Michael Cawley, PharmD, discusses why pharmacists should treat a device that delivers three COPD medications with caution.
The FDA has approved a once-daily inhalable solution for the treatment of chronic obstructive pulmonary disease.
Research found that medication nonadherence is likely among patients with chronic obstructive pulmonary disease.
Patients with chronic obstructive pulmonary disease may experience significantly fewer acute exacerbations when a long-acting muscarinic antagonist is added to a long-acting beta agonist than when an inhaled corticosteroid is added, according to an analysis of data from the FLAME and LANTERN Studies.
AstraZeneca announced that it received approval for glycopyrrolate and formoterol fumarate (Bevespi Aerosphere) inhalation aerosol.